Fleury and Bradsaúde Form FleuryOnco to Open Seven Oncology Clinics by 2027

Fleury and Atlântica Hospitais, controlled by Bradsaúde, created FleuryOnco, a company focused on outpatient oncology treatment, with Fleury holding 50.01% and Bradsaúde 49.99%. The partners will share an initial investment of R$72 million to open seven oncology clinics in São Paulo and Rio de Janeiro between December 2025 and the end of 2027, Brazil Journal reported on November 10, 2026.

FleuryOnco's Two Brands and Seven Clinics

FleuryOnco will operate under two brands. Fleury Oncologia will have two clinics in São Paulo aimed at the premium segment, while OncoOne will have five clinics for the premium and intermediate segments, described as middle and upper-middle class, in São Paulo and Rio de Janeiro. The clinics will serve Bradsaúde's clients but not exclusively, and Fleury's CEO said there will be negotiations with other health plans.

The new company will offer consultations, diagnostics, drug infusion, treatments such as chemotherapy and immunotherapy, and services from professionals including nutritionists and psychologists. Fleury and Atlântica are already partners in Croma Oncologia, a joint venture with Beneficência Portuguesa launched in 2024.

Fleury's CEO Jeane Tsutsui said the market is large and tends to grow with population aging and other risk factors. "Há espaço para uma nova empresa," she told Brazil Journal. Bradsaúde CEO Carlos Marinelli said scale is also fundamental. "A escala também é fundamental, porque permite que sejamos mais competitivos, por exemplo, na compra de medicamentos," he said.

Estimates from the two companies indicate that revenues linked to cancer treatments in Brazil should reach R$60 billion this year, with outpatient care accounting for about 70% of that total. There is no revenue expectation for the new company, and its result will be consolidated in Fleury's balance sheet. Services outside diagnostics, such as orthopedics and ophthalmology, account for about 8% of Fleury's revenues, down from around 10% before the Hermes Pardini acquisition in 2023.

Fleury's Health Group Consolidation

According to akta.pro company records, Bradesco announced in February 2026 the consolidation of all its healthcare assets, including health and dental insurance, hospital investments in Atlântica and Grupo Santa, and diagnostics through the Fleury group, into a new listed entity called BradSaúde via a reverse IPO through Odontoprev. The records describe the combined entity as having pro forma 2025 revenue of R$52 billion. Bradesco controls Bradsaúde and holds 25% of Fleury's capital, Brazil Journal reported.

Fleury's Earlier Deals

In October 2026, Fleury agreed to acquire 100% of Unilab Laboratório Clínico for R$55 million in enterprise value, a deal dated May 1 that uses a 0.85 EV/revenue multiple and a 4.3 EV/EBITDA multiple, with revenue of R$65 million for the trailing 12 months, InfoMoney reported. In November 2025, Fleury acquired 100% of Femme Laboratory (GIP Medicina Diagnóstica) for R$207.5 million, extending its women's health vertical, according to akta.pro company records.

FleuryOnco's Clinic Rollout

The first FleuryOnco clinics are scheduled to open in December 2025, with the seven-clinic network planned for completion by the end of 2027.